Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics

被引:107
|
作者
Patrick, K. S. [1 ]
Straughn, A. B.
Minhinnett, R. R.
Yeatts, S. D.
Herrin, A. E.
DeVane, C. L.
Malcolm, R.
Janis, G. C.
Markowitz, J. S.
机构
[1] Med Univ S Carolina, Dept Pharmaceut Sci, Charleston, SC 29425 USA
[2] Univ Tennessee, Dept Pharmaceut, Memphis, TN 38163 USA
[3] Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, Charleston, SC 29425 USA
[4] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA
[5] MEDTOX Labs, St Paul, MN USA
关键词
D O I
10.1038/sj.clpt.6100082
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This study explores the hypotheses that: (1) ethanol will interact with di-Methylphenidate (MPH) to enantioselectively elevate plasma d-MPH, and primarily yield l-ethylphenidate as a transesterification metabolite; (2) women will exhibit lower relative bioavailability of MPH than men; and (3) sex-dependent differences in subjective effects will exist. dI-MPH HCl (0.3 mg/kg) was administered orally 30 min before ethanol, 30 min after ethanol (0.6 gm/kg), or without ethanol, in a randomized, normal subject three-way crossover study of 10 men and 10 women. Pharmacokinetic parameters were compared. Subjective effects were recorded using visual analog scales. One subject was a novel poor MPH metabolizer whose data were analyzed separately. Ethanol after or before MPH significantly (P < 0.0001) elevated the geometric mean for the maximum d-MPH plasma concentration (C-max (+/- SD)) from 15.3 (3.37) ng/ml to 21.5 (6.81) and 21.4 (4.86), respectively, and raised the corresponding geometric mean for the area under the concentration-time curve values from 82.9 (21.7) ng ml/h to 105.2 (23.5) and 102.9 (19.2). I-MPH was present in plasma only at 1-3% of the concentration of d-MPH, except in the poor metabolizer where I-MPH exceeded that of d-MPH. The metabolite l-ethylphenidate frequently exceeded 1 ng/ml in plasma, whereas d-ethylphenidate was detected only in low pg/ml concentrations. Women reported a significantly greater stimulant effect than men when questioned "Do you feel any drug effect?" (P < 0.05), in spite of lower mean plasma d-MPH area under the response-time curves in women. Ethanol elevates plasma d-MPH C-max and area under the concentration-time curve by approximately 40% and 25%, respectively. If the poor metabolizer of MPH proves to be a distinct phenotype, determining the genetic mechanism may be of value for individualizing drug therapy. The more pronounced stimulant effects experienced by women have sex-based abuse liability implications.
引用
收藏
页码:346 / 353
页数:8
相关论文
共 50 条
  • [1] Influence of gender on the pharmacokinetics and pharmacodynamics of drugs
    Thurmann, PA
    Hompesch, BC
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 1998, 36 (11) : 586 - 590
  • [2] Pharmacokinetics and pharmacodynamics of methylphenidate enantiomers in rats
    Aoyama, T
    Kotaki, H
    Sawada, Y
    Iga, T
    [J]. PSYCHOPHARMACOLOGY, 1996, 127 (02) : 117 - 122
  • [3] PharmGKB summary: methylphenidate pathway, pharmacokinetics/pharmacodynamics
    Stevens, Tyler
    Sangkuhl, Katrin
    Brown, Jacob T.
    Altman, Russ B.
    Klein, Teri E.
    [J]. PHARMACOGENETICS AND GENOMICS, 2019, 29 (06): : 136 - 154
  • [4] Influence of ethanol and gender on methylphenidate bioavailability, metabolism and response.
    Patrick, KS
    DeVane, CL
    Malcolm, RJ
    Minhinnett, RR
    Markowtiz, JS
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (09): : 1083 - 1083
  • [5] Influence of ethanol on the pharmacokinetics of methylphenidate's metabolites ritalinic acid and ethylphenidate
    Koehm, Michaela
    Kauert, Gerold F.
    Toennes, Stefan W.
    [J]. ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH, 2010, 60 (05): : 238 - 244
  • [6] Influence of age, gender, and race on pharmacokinetics, pharmacodynamics, and safety of fesoterodine
    Malhotra, B. K.
    Wood, N.
    Sachse, R.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2009, 47 (09) : 570 - 578
  • [7] The influence of age, gender and BMI on the pharmacokinetics and pharmacodynamics of vildagliptin.
    He, YL
    Sabo, R
    Wang, Y
    Campestrini, J
    Rivere, GL
    Saltzman, M
    Ligueros-Saylan, M
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (02) : P63 - P63
  • [8] GENDER EFFECTS IN PHARMACOKINETICS AND PHARMACODYNAMICS
    HARRIS, RZ
    BENET, LZ
    SCHWARTZ, JB
    [J]. DRUGS, 1995, 50 (02) : 222 - 239
  • [9] Gender Differences in Pharmacokinetics and Pharmacodynamics
    Wiener, H.
    [J]. JOURNAL FUR HYPERTONIE, 2008, 12 (02): : 22 - 25
  • [10] Gender differences in pharmacokinetics and pharmacodynamics
    Beierle, I
    Meibohm, B
    Derendorf, H
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 1999, 37 (11) : 529 - 547